Definitive Contract 75F40122C00180
Award Date
9/21/22
Potential Completion Date
9/29/23
Potential Value
$292K
Federal Agency
Food and Drug Administration
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Silver Spring, MD 20993, USA
Solicitation Procedures
Basic Research
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm-fixed-price contract awarded by the Food and Drug Administration (FDA) to Institute For Clinical Pharmacodynamics, Inc., a minority-owned for-profit organization based in Schenectady, New York. The contract, valued at $263,016.10, is for the development of modernized susceptibility guidance for the antibiotics ampicillin and vancomycin for Enterococcus species using pharmacometric approaches. The contract has an ultimate completion date of June 24, 2025. Institute For Clinical...
This $291,142 firm fixed price prime contract was awarded by the Food and Drug Administration (FDA), a civilian agency, to the Institute For Clinical Pharmacodynamics, Inc. to conduct research on updating susceptibility guidance for the oral antibiotics sulfamethoxazole-trimethoprim. The contract supports the agency's efforts to develop modernized susceptibility guidance using pharmacometric approaches. No set-aside designation was used for this award. The Institute For Clinical...
This is a cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Curia Global Inc. (doing business as Amri). The order is for the completion of the synthesis of 400 grams of non-GMP (good manufacturing practice) antibiotic candidate FG-960-2. The total ceiling value of the order is $154,712.13, with a period of performance ending on January 30, 2021. This order is part of a larger...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $24,143,894.00 cost-plus-fixed-fee contract to the Research Triangle Institute (RTI International), a non-profit research organization, to establish the Chemistry Center for Combating Antibiotic-Resistant Bacteria (CC4CARB). The CC4CARB will coordinate the design, synthesis, and delivery of novel small molecule libraries targeting Gram-negative bacteria to support antibacterial drug discovery programs. The contract has a...
This is a $315,945.00 firm fixed price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to Southern Research Institute for "IN VITRO ASSESSMENTS FOR ANTIMICROBIAL ACTIVITY". The contract is a task order under NIAID's larger "In Vitro Antimicrobial Assessments 2011-2018" indefinite delivery/indefinite quantity (IDIQ) contract vehicle. The contract does not have a set-aside...
This is a $1,130,545.46 firm fixed-price contract awarded by the Food and Drug Administration (FDA) to Icon Clinical Research LLC, a global provider of outsourced clinical development services. The contract is titled "Evaluation of the Measurement Properties of Patient-Reported Outcome (PRO) Instruments in Patients with Community-Acquired Bacterial Pneumonia (CABP), Hospital-Acquired Bacterial Pneumonia (HABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI)" and has a...
The University of Wisconsin-Madison was awarded a $353,326 firm fixed price definitive contract by the Department of Health and Human Services Food and Drug Administration to develop modernized susceptibility guidance for oral cephalosporin antimicrobial agents using pharmacometric approaches. This award responds to the FDA's FY22 Broad Agency Announcement for Advanced Research and Development of Regulatory Science, which sought proposals to advance regulatory science in nine areas of interest...
This is a $3,940,013.28 Definitive Contract awarded by the Food and Drug Administration (FDA) to International Consulting Associates, Inc. (ICA), an SBA-certified 8(a), minority-owned, small disadvantaged business. The contract is for post-market safety studies and has a completion date of March 20, 2022. It is an 8(a) sole source award. ICA is a specialized healthcare IT and management consulting firm that has an extensive track record of supporting federal health agencies like the FDA and...
This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Curia Global Inc. (doing business as Amri), a for-profit organization and manufacturer of goods. The award, valued at $610,340.86, is a delivery order under the Nonclinical Services for Development of Interventional Agents indefinite-delivery, indefinite-quantity (IDIQ) contract. The contract directs Curia to prepare 400 grams of non-GMP (good manufacturing practice)...
The U.S. Food and Drug Administration (FDA) awarded a $1,155,442.55 Cost Plus Fixed Fee contract to Cubrc, Inc. to conduct research and development on the "Immunogenicity Risk of Peptide Drug Generics and Their Impurities: In Silico and In Vitro Assessment and Validation Methods." The contract, which has a period of performance ending September 27, 2022, was issued under the FDA's Broad Agency Announcement (BAA) solicitation for advanced research and development to support regulatory...